Truist Securities Expects Q2 Beat from Eli Lilly; Price Target, Estimates Up
() -- Truist Securities revised its model for Eli Lilly (LLY.SW, LLY.F), raising its price target and earnings forecast for the pharmaceutical giant, as analysts anticipate a "beat and raise" second quarter. "We note strong US script growth (Zepbound/ Mounjaro) offset by [slower-than-expected Foundayo growth]. We maint